Therapeutic compositions containing macitentan

Abstract

The invention relates to a product containing the compound of formula (I) below or a pharmaceutically acceptable salt of this compound, in combination with at least one compound having prostacyclin receptor (IP) agonist properties, or a pharmaceutically acceptable salt thereof.

The invention claimed is: 
     
       1. A method for the treatment of a disease selected from hypertension, pulmonary hypertension, diabetic arteriopathy, heart failure, erectile dysfunction, angina pectoris and pulmonary fibrosis, comprising administering macitentan, in free or pharmaceutically acceptable salt form, in combination with an effective amount of at least one compound having prostacyclin receptor (IP) agonist properties, or a pharmaceutically acceptable salt thereof, wherein the compound having prostacyclin receptor (IP) agonist properties is selected from iloprost and its pharmaceutically acceptable salts. 
     
     
       2. The method according to  claim 1 , wherein the macitentan and the compound having prostacyclin receptor (IP) agonist properties are administered simultaneously, separately or over a period of time. 
     
     
       3. The method according to  claim 2 , wherein the macitentan and the compound having prostacyclin receptor (IP) agonist properties are administered simultaneously. 
     
     
       4. The method according to  claim 2 , wherein the macitentan and the compound having prostacyclin receptor (IP) agonist properties are administered separately. 
     
     
       5. The method according to  claim 2 , wherein the macitentan and the compound having prostacyclin receptor (IP) agonist properties are administered over a period of time. 
     
     
       6. The method according to  claim 1 , wherein the disease is pulmonary hypertension. 
     
     
       7. The method according to  claim 1 , wherein the disease is pulmonary arterial hypertension. 
     
     
       8. The method according to  claim 7 , wherein the macitentan is in free form. 
     
     
       9. A method for the treatment of pulmonary arterial hypertension comprising administering an effective amount of macitentan in free or pharmaceutically acceptable salt form, in combination with iloprost, in free or pharmaceutically acceptable salt form. 
     
     
       10. The method according to  claim 9 , wherein the macitentan and the iloprost are administered simultaneously. 
     
     
       11. The method according to  claim 9 , wherein the macitentan and the iloprost are administered separately. 
     
     
       12. The method according to  claim 9 , wherein the macitentan and the iloprost are administered over a period of time. 
     
     
       13. The method according to  claim 9 , wherein the macitentan is administered once a day.